SCHEMBL948303

SCHEMBL948303

CC(=O)Nc1ccc2cc(S(=O)(=O)CCC(=O)O)ccc2c1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.78
ALDH1A1 P00352 6/20 0.62
KMT2A Q03164 4/20 0.62
MAPT P10636 2/20 0.62
POLB P06746 2/20 0.62
HTT P42858 3/20 0.55
NPSR1 Q6W5P4 1/20 0.55
TP53 P04637 1/20 0.51
HPGD P15428 1/20 0.50
MEN1 O00255 3/20 0.49
NPC1 O15118 1/20 0.48
GLA P06280 1/20 0.48
TNNI3 P19429 1/20 0.48
TNNT2 P45379 1/20 0.48
RAB9A P51151 1/20 0.48
TNNC1 P63316 1/20 0.48
RUNX1 Q01196 1/20 0.48
CBFB Q13951 1/20 0.48
CYP1A2 P05177 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1199964 0.88 KDM4E (1.00) KDM4EALDH1A1KMT2AMAPTPOLB
SCHEMBL9518669 0.86 ALDH1A1 (0.57) KDM4EALDH1A1KMT2AMAPTPOLB
SCHEMBL7826055 0.79 ALDH1A1 (0.68) KDM4EALDH1A1HTTNPSR1HPGD
SCHEMBL9746587 0.79 ALDH1A1 (0.54) KDM4EALDH1A1KMT2AMAPTPOLB
SCHEMBL9495391 0.79 TP53 (0.49) KDM4EALDH1A1KMT2AMAPTPOLB
SCHEMBL8973399 0.78 POLB (0.56) KDM4EALDH1A1KMT2APOLBNPSR1
SCHEMBL10752864 0.77 ALDH1A1 (1.00) KDM4EALDH1A1KMT2AMAPTPOLB
SCHEMBL950400 0.77 SNCA (0.59) KDM4EKMT2AMAPTPOLBMEN1
SCHEMBL947731 0.77 ALDH1A1 (0.56) KDM4EALDH1A1HTTNPSR1HPGD
SCHEMBL948719 0.77 ALDH1A1 (0.56) KDM4EALDH1A1KMT2APOLBHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110009389-A1 IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-01-13 US disclosed
US-20070004736-A1 Imidazole derivative, process for producing the same, and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-01-04 US disclosed
EP-1564213-A1 IMIDAZOLE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Pharmaceutical Company Limited (JP) 2005-08-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070004736-A1 Imidazole derivative, process for producing the same, and use HRH4, F2, HRH2 KDM4E 1356/4885ALDH1A1 2246/4885KMT2A 417/4885
US-20110009389-A1 IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE F2, H1-3, CYC1 KDM4E 1558/4885ALDH1A1 2316/4885KMT2A 491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.